To scroll text in this page

Global Navigation
Global Navigation end

link:Social Responsibility

Start of the main text
Field of
CSR-based
Management
Review of Fiscal 2015 Initiatives Page in Annual Report Activities to be Tackled in Fiscal 2016
Main Activities and Results Relevant Material Issues
Business
Activities
  • Compiled Position on Expanded Access to Investigational Medicines
  • Supported the doping prevention activities of the World Anti-Doping Agency
  • Expanded the scope of education and training programs on the safety of pharmaceutical products to all employees including contractors of affiliates
  • Improvement of healthcare infrastructure and services to solve Access to Health issues
  • Socially responsible R&D
  • Proper use of products
  • Announce Position on Expanded Access to Investigational Medicines
  • Further strengthen the quality assurance system
  • Promote anti-doping activities
  • Globally operate a new medical information system for responding to inquiries
Employees
  • Formulated a medium- to long-term plan and targets for improving the ratio of female managers at Astellas Pharma Inc.
  • Conducted engagement surveys which include globally common questionnaires in Japan, the Americas, EMEA and Asia & Oceania
  • Diversity and equal opportunity
  • Recruitment and retention of employees
  • Promote various measures aimed at encouraging women’s success in Japan
  • Make preparations to conduct a globally common engagement survey
Society
  • Signed a new collaborative research agreement with the National Institute of Advanced Industrial Science and Technology to discover anti-protozoan parasite drugs for the treatment of Chagas disease, one of the neglected tropical diseases
  • Signed a new collaborative development agreement with the Institute of Medical Science, the University of Tokyo on a rice-based oral vaccine against diarrheal diseases caused by cholera and enterotoxigenic Escherichia coli
  • Continued to implement Changing Tomorrow Day with attendance of more than 7,400 employees worldwide
  • Societal benefit-driven product development
  • Philanthropic community support
  • Promote collaborative research to discover anti-protozoan parasite drugs for the treatment of Chagas disease
  • Promote collaborative research of a rice-based oral vaccine
  • Continue implementation of Changing Tomorrow Day
Environment
  • Greenhouse gas (GHG) emissions came to 162,000 tons, down 30.8% from the fiscal 2005 level. (Global target: reduce GHG emissions by 35% or more from the fiscal 2005 level by the end of fiscal 2020)
  • Water withdrawal amounted to 10,269 m3, 76.3% of the level in fiscal 2005, achieved the global target. (Global target: reduce water withdrawal to 80% or less of the fiscal 2005 level by the end of fiscal 2015)
  • Biodiversity Index came in at 3.18 times the figure recorded in fiscal 2005, achieved the global target. (Global target: raise the Index to triple the fiscal 2005 level by the end of fiscal 2020)
  • All other reduction targets for the end of fiscal 2015 (CO2 emissions from sales fleets, electricity usage at our offices, the final volume of landfill waste, and the amount of volatile organic compounds (VOCs) discharged) were achieved.
  • Efficient use of energy and reduction of GHG emissions
  • Water usage reduction
  • Biodiversity
  • Continue initiatives to achieve the Environmental Action Plan targets (Numerical targets for the end of fiscal 2020: Reduce GHG emissions and improve the Biodiversity Index)
    (Numerical targets added due to revisions based on results for fiscal 2015: Increase water resources productivity and reduce waste discharge per unit of sales)
Ethics &
Compliance
  • Established global policies including rules on harassment, data privacy, and medical affairs and commercial activities
  • Ongoing implementation of compliance training on harassment, data privacy, anti-corruption and anti-bribery, and other areas
  • Established a structure for providing appropriate medical and product information
  • Promoted compliance management among third parties
  • Customer privacy
  • Business ethics and fair competition
  • Compliance with laws and regulations
  • Revise the Code of Conduct
  • Formulate and develop various global policies
  • Continue to implement compliance training